[go: up one dir, main page]

CY1116662T1 - Μεθοδοι χρησης αναστολεων alk - Google Patents

Μεθοδοι χρησης αναστολεων alk

Info

Publication number
CY1116662T1
CY1116662T1 CY20151100758T CY151100758T CY1116662T1 CY 1116662 T1 CY1116662 T1 CY 1116662T1 CY 20151100758 T CY20151100758 T CY 20151100758T CY 151100758 T CY151100758 T CY 151100758T CY 1116662 T1 CY1116662 T1 CY 1116662T1
Authority
CY
Cyprus
Prior art keywords
methods
alk
use alk
eml4
crisotinib
Prior art date
Application number
CY20151100758T
Other languages
English (en)
Inventor
Nanxin Li
Jennifer L Harris
Peter Mcnamara
Fangxian Sun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116662(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116662T1 publication Critical patent/CY1116662T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση παρέχει μεθόδους για χρήση ενώσεων του Χημικού τύπου (I) για τη θεραπεία μιας κατάστασης που προκαλείται από EML4-ALK+, όπως είναι ο μικροκυτταρικός καρκίνος του πνεύμονα από EML4-ALK+, και οι οποίες είναι επιλεκτικά ανθεκτικές στην κριζοτινίβη ˙ όπου τα R1, R2, R3, R4, R5 και R6 είναι όπως ορίστηκαν πιο πάνω.
CY20151100758T 2011-02-02 2015-08-28 Μεθοδοι χρησης αναστολεων alk CY1116662T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
EP12703670.5A EP2670401B1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (1)

Publication Number Publication Date
CY1116662T1 true CY1116662T1 (el) 2017-03-15

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100758T CY1116662T1 (el) 2011-02-02 2015-08-28 Μεθοδοι χρησης αναστολεων alk

Country Status (22)

Country Link
US (1) US8703787B2 (el)
EP (1) EP2670401B1 (el)
JP (1) JP5837095B2 (el)
KR (1) KR101521861B1 (el)
CN (1) CN103458881B (el)
AU (1) AU2012212142B2 (el)
BR (1) BR112013019643B1 (el)
CA (1) CA2824092C (el)
CY (1) CY1116662T1 (el)
DK (1) DK2670401T3 (el)
EA (1) EA023404B1 (el)
ES (1) ES2543567T3 (el)
HR (1) HRP20150946T1 (el)
HU (1) HUE025395T2 (el)
ME (1) ME02200B (el)
MX (1) MX2013008791A (el)
PL (1) PL2670401T3 (el)
PT (1) PT2670401E (el)
RS (1) RS54189B1 (el)
SI (1) SI2670401T1 (el)
SM (1) SMT201500300B (el)
WO (1) WO2012106540A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6359020B6 (ja) 2012-11-06 2018-08-15 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Ａｌｋキナーゼ阻害剤
AU2013341271A1 (en) * 2012-11-07 2015-05-14 Novartis Ag Combination therapy
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
TWI610923B (zh) 2013-07-11 2018-01-11 Betta Pharmaceuticals Co Ltd 酪氨酸蛋白激酶調節劑及其應用方法
JP6479812B2 (ja) * 2013-08-28 2019-03-06 ノバルティス アーゲー 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
JP6622726B2 (ja) * 2014-06-17 2019-12-18 コリア リサーチ インスティチュート オブ ケミカル テクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃｈｅｍｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ ピリミジン‐２，４‐ジアミン誘導体及びそれを有効成分として含有する抗癌用医薬組成物
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
EP3287463A4 (en) 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
WO2018044767A2 (en) 2016-08-29 2018-03-08 The Regents Of The University Of Michigan Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
DK2287156T3 (da) * 2003-08-15 2013-08-26 Novartis Ag 2,4-Di(phenylamino)-pyrimidiner egnede i behandling af neoplastiske sygdomme, inflammatoriske lidelser og lidelser i immunsystemet
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP2055146B1 (en) 2006-07-10 2013-11-20 Goji Limited Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
JP5298187B2 (ja) * 2008-04-07 2013-09-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物

Also Published As

Publication number Publication date
BR112013019643A2 (pt) 2016-10-04
KR20130121174A (ko) 2013-11-05
ES2543567T3 (es) 2015-08-20
HUE025395T2 (en) 2016-02-29
DK2670401T3 (en) 2015-09-07
MX2013008791A (es) 2013-10-07
SI2670401T1 (sl) 2015-10-30
CA2824092C (en) 2020-06-30
US20130296357A1 (en) 2013-11-07
WO2012106540A1 (en) 2012-08-09
JP2014504646A (ja) 2014-02-24
CA2824092A1 (en) 2012-08-09
AU2012212142A1 (en) 2013-08-15
PT2670401E (pt) 2015-10-12
EA201391114A1 (ru) 2013-12-30
CN103458881A (zh) 2013-12-18
US8703787B2 (en) 2014-04-22
EP2670401A1 (en) 2013-12-11
ME02200B (me) 2016-02-20
JP5837095B2 (ja) 2015-12-24
RS54189B1 (sr) 2015-12-31
EA023404B1 (ru) 2016-05-31
AU2012212142B2 (en) 2015-09-24
SMT201500300B (it) 2016-01-08
HRP20150946T1 (hr) 2015-10-09
KR101521861B1 (ko) 2015-05-21
EP2670401B1 (en) 2015-06-10
CN103458881B (zh) 2015-08-12
PL2670401T3 (pl) 2015-11-30
BR112013019643B1 (pt) 2022-04-19

Similar Documents

Publication Publication Date Title
CY1116662T1 (el) Μεθοδοι χρησης αναστολεων alk
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
CY1119531T1 (el) Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
CY1119620T1 (el) Αναστολεις νεπριλυσινης
IN2015DN00960A (el)
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1120355T1 (el) Αναστολεις toy iap
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MY169267A (en) New aryl-quinoline derivatives
MX2012008141A (es) Compuestos y metodos.
CY1117843T1 (el) Νεα παραγωγα θειενοπυριμιδινης, διεργασιες για την παρασκευη αυτων και θεραπευτικες χρησεις αυτων
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
PH12015500399A1 (en) Azaindolines
MX342311B (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.